A vaccine for the highly contagious group A streptococcus bacterium (Strep A) has moved a step closer to reality, an MHRA study has found.
The study, led by the Medicines and Healthcare products Regulatory Agency (MHRA) along with the GSK Vaccines Institute for Global Health, tested an innovative approach to vaccination that could lead to the development of a vaccine against Strep A.
Strep A is a major global cause of sore throat, scarlet fever, invasive infections and rheumatic heart disease. There is currently no licensed vaccine for Strep A, despite it causing hundreds of millions of infections globally. Although most Strep infections are mild, serious complications can lead to long-term disability or death, particularly in low- and middle-income countries where the burden of the disease remains high.
GMMA-based vaccine hope
The vaccine used generalised modules for membrane antigens (GMMA). These are tiny bubbles naturally shed from bacteria, as both a carrier for the Strep A carbohydrate and an adjuvant to boost the immune response.
Based on a mouse model, the study found this showed promise for a potential Strep A vaccine which could be administered in the nose or under the tongue.
Unlike most vaccine approaches, which focus primarily on generating antibodies in the bloodstream, the MHRA’s study targeted immunity at mucosal surfaces of the nose and throat, where Strep A establishes infection.
“This research highlights the potential of GMMA technology to support a new generation of affordable, needle-free vaccines,” said Fatme Mawas, group leader for polysaccharides and conjugate vaccines at the MHRA. “By delivering a Strep A vaccine through the nose or under the tongue, we showed that strong immune responses were generated both at the mucosal surfaces where infection begins and throughout the body, supporting protection against invasive disease.”
She added: “This approach could make vaccines easier to administer and more accessible globally, particularly in low- and middle-income countries where the burden of Strep A disease is greatest. By preventing infections before they occur, vaccines can also reduce antibiotic use and support efforts to tackle antimicrobial resistance.”



